Agilent Technologies to Acquire Cartagenia, Leading Provider of Software to Enable Clinical Analysis of Genomics Data

Agilent Technologies to Acquire Cartagenia, Leading Provider of Software to Enable Clinical Analysis of Genomics Data

SANTA CLARA, Calif., and BOSTON, May 4, 2015 – Agilent Technologies Inc. (NYSE: A) and Cartagenia today announced that they have signed a definitive agreement under which Agilent will acquire Cartagenia, a leading provider of software and services for clinical genetics and molecular pathology labs.

Cartagenia, which has offices in Leuven, Belgium, and Boston, Massachusetts, provides software solutions for variant assessment and reporting of clinical genomics data from next-generation sequencing and microarrays.  Uniquely geared to routine clinical labs, Cartagenia's solutions are FDA-registered as exempt Class I Medical Devices in the U.S. and as Class I Medical Devices in Europe. The Cartagenia Bench platform enables technicians, lab directors and clinicians to visualize, assess and report clinical genetics data in the context of patient information.

With Cartagenia Bench, labs can build an internal knowledge base, build variant assessment SOPs, automate report drafting, and access a wide range of community-validated, private and premium content resources, whether for oncology or inherited disease.

Cartagenia's platform also provides deep support for consortia of collaborating labs. Data-sharing has become an essential requirement for the community, and through private and public consortia, users can connect and pool their knowledge on rare diseases and actionable findings.

"Cartagenia's approach to enabling the interpretation of clinical genomics data is revolutionary," said Jacob Thaysen, president of Agilent's Diagnostics and Genomics Group. "We look forward to providing Cartagenia's software solutions  to our clinical genetics and molecular oncology customers and to providing Cartagenia's existing customers with access to our global service and support network. Together, Agilent and Cartagenia can help remove bottlenecks inherent in analysis, interpretation and reporting clinical data—resulting in faster answers for patients."

"Joining forces with Agilent is an excellent strategic fit and provides tremendous opportunity both for our customers—who will benefit from integration with a broad family of solutions and a range of new applications—and for our  team, as we'll be able to further accelerate our success and growth through Agilent's global reach and leading footprint in clinical labs," said Herman Verrelst, chief executive officer, Cartagenia.

The acquisition is expected to be completed May 19, subject to local laws and regulations and customary closing conditions. Cartagenia employs 36 people, all of whom will be offered employment with Agilent.

Financial terms of the transaction were not disclosed.

[email protected]